Home > Healthcare > Medical Devices > Medical Supplies > U.S. Cancer Contrast Media Market

U.S. Cancer Contrast Media Market Trends

Report ID: GMI8339
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

U.S. Cancer Contrast Media Market Trends

Technological advancements in cancer contrast media have revolutionized the field of oncology by significantly improving the accuracy and efficacy of cancer diagnosis, staging, and treatment monitoring.

Significant progress has been made in designing and formulating contrast agents, resulting in versions that exhibit heightened specificity for cancerous tissues. These advanced agents have the capability to target biomarkers or receptors that are overexpressed in cancer cells.
Furthermore, advances in imaging modalities such as MRI and CT scanner have enabled multiparametric imaging techniques. These techniques combine different imaging sequences or modalities along with the use of multiple contrast agents to provide comprehensive information about tumor biology, including its microenvironment, vascularity, and metabolic activity.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of U.S. cancer contrast media reached USD 2.4 billion in 2023 and is set to witness 4.9% CAGR during 2024 to 2032, propelled by the increasing prevalence of cancer coupled with the growing technological advancements.

The CT scan segment is projected to account for USD 1.2 billion in revenue by 2032, owing to its increasing use for monitoring the response to cancer treatment longitudinally and getting detailed insights into treatment efficacy and progression.

U.S. cancer contrast media industry from breast cancer application segment accounted for 24.1% revenue share in 2023, due to the rising prevalence of breast cancer in the U.S.

Some of the top cancer contrast media companies in the U.S. include Bayer AG, Bracco Imaging S.p.A., GE Healthcare Technologies Inc, Guerbet, iMAX Diagnostic Imaging, Lantheus Medical Imaging, nanoPET Pharma GmbH, Subtle Medical, Inc., Telix Pharmaceuticals Limited, and Trivitron Healthcare.